Patents
Literature
2 results about "Argatroban" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.
Anticoagulant biomaterials for blood purification and methods of making and using the same
The application discloses an anticoagulant biomaterial for blood purification and a preparation method and application thereof, and comprises the following steps: providing an amphiphilic copolymer P(AA-MMA); blending polyethersulfone, P(AA-MMA) and a solvent, stirring at a set temperature to obtain a casting solution, and preparing a blending membrane from the casting solution; soaking the blending membrane in a 2-morpholine-4-yl ethanesulfonic acid buffer solution containing argatroban, 1-ethyl-(3-dimethylaminopropyl) carbonyl diimide and hydroxy succinimide, and reacting at room temperature to obtain an argatroban grafted blending membrane, namely the anticoagulant biomaterial. The method improves the hydrophilicity of the membrane, reduces the albumin adsorption of the membrane, reduces the adhesion of platelets on the membrane, prolongs the coagulation time APTT, PT and TT of the membrane, and is better in biocompatibility and enhanced in anticoagulation performance.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Blood purification and anticoagulation function polyether sulfone-based material, preparation method and application thereof
PendingCN122127600ASemi-permeable membranesOther blood circulation devicesExtracorporeal circulationHemotoxin
This invention relates to the field of biomedical polymer materials technology, specifically to a polyethersulfone-based material with blood purification and anticoagulation functions, its preparation method, and its applications. The polyethersulfone-based material uses polyethersulfone as the main component, and a stable multi-coordination network structure is constructed by introducing terpyridine ligands and multivalent metal ions at the molecular level. Furthermore, the anticoagulant active molecules argatroban or heparin are immobilized on its surface, achieving selective adsorption of blood toxins and synergistic regulation of the anticoagulation reaction. The material is prepared using a process combining phase inversion membrane formation technology and surface coordination modification, resulting in a composite interface on the membrane surface rich in hydrophilic groups and a stable anticoagulant layer, significantly improving blood compatibility and membrane flux stability. This composite membrane can simultaneously perform purification and anticoagulation functions in hemodialysis, hemofiltration, and extracorporeal circulation systems, exhibiting good mechanical strength, chemical stability, and biosafety. The preparation route of this invention is simple, the parameters are controllable, and it is suitable for large-scale production.
Owner:HUAIBEI NORMAL UNIVERSITY